Polycystic ovary syndrome refers to an imbalance of hormone that causes mood disorders, metabolic syndrome, insulin resistance and obstructive sleep apnea. An absence of ovulation, high levels of androgens, and cyst formation in both ovaries are observed in most of the patients with polycystic ovary syndrome. The disease is also the major cause of anovulatory infertility, causing trouble in women to conceive naturally. Unwanted hair growth, weight gain, dark patches, acne and irregular bleeding is observed in most of the patients suffering with polycystic ovary syndrome. The disease can be treated by progestin therapy and combination birth control pills. Novartis AG is in the process of developing LIK066 as a sodium-glucose transporter 1 inhibitor for the treatment of polycystic ovary syndrome. Dexa Medica Group is in the process of developing DLBS3233 as a GLUT4 stimulant for the treatment of the disease. Some of the companies having a pipeline of polycystic ovary syndrome include Novartis AG, Dexa Medica Group, Bayer AG, and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.